Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATB-1011 and ATB-1012 in Essential Hypertension and Type II Diabetes Mellitus
NCT05573477Phase 3Completed
- Sponsor
- Autotelic Bio
- Start
- Nov 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olmesartan, dapagliflozin in essential hypertension, type 2 diabetes mellitus (T2DM), sponsored by Autotelic Bio. Started Nov 2022; status: completed.
02
Drugs
olmesartandapagliflozin
03
Conditions
essential hypertensiontype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05573477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05573477.